Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

20 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy of regorafenib in the second-and third-line setting for patients with advanced hepatocellular carcinoma: A real life data of multicenter study from Turkey.
Bekir Hacioglu M, Kostek O, Karabulut S, Tastekin D, Sezgin Goksu S, Alandag C, Akagunduz B, Bilgetekin I, Caner B, Bilgehan Sahin A, Yildiz B, Kose F, Kaplan MA, Gulmez A, Dogan E, Can Guven D, Gurbuz M, Ergun Y, Karaagac M, Gokcen Demiray A, Turker S, Sakalar T, Ozkul O, Telli TA, Sahin S, Kilickap S, Bilici A, Erdogan B, Cicin I. Bekir Hacioglu M, et al. Among authors: sezgin goksu s. J BUON. 2020 Jul-Aug;25(4):1897-1903. J BUON. 2020. PMID: 33099930 Free article.
Prognostic factors in clinical stage T4N2 locally advanced non-small cell lung cancer.
Arslan D, Tural D, Koca T, Tastekin D, Kaymak Cerkesli A, Basaran H, Gunduz S, Murat Tatli A, Sezgin Goksu S, Uysal M, Kargi A, Kargi B, Koral L, Ibrahim Bassorgun C, Unal D, Mutlu H, Senol Coskun H, Ozdogan M, Bozcuk H. Arslan D, et al. Among authors: sezgin goksu s. J BUON. 2015 Mar-Apr;20(2):573-9. J BUON. 2015. PMID: 26011352 Free article.
Bevacizumab in recurrent ovarian cancer.
Sait Bakir M, Birge O, Karadag C, Ilhan Y, Aykut Tuncer H, Sezgin Göksu S, Simsek T. Sait Bakir M, et al. Among authors: sezgin goksu s. J BUON. 2021 Jul-Aug;26(4):1271-1278. J BUON. 2021. PMID: 34564981 Free article.
Real-Life Analysis of Efficacy and Safety of Everolimus Plus Exemestane in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2-Negative Metastatic Breast Cancer Patients: A Turkish Oncology Group (TOG) Study.
Bilici A, Uysal M, Menekse S, Akin S, Yildiz F, Turan M, Sezgin Goksu S, Beypinar I, Sakalar T, Değirmenci M, Erdem D, Basaran G, Olmez OF, Avci N, Tural D, Sakin A, Turker S, Demir A, Temiz S, Kaplan MA, Dogan M, Tanriverdi O, Bilgetekin I, Cinkir HY, Acikgoz O, Paydas S, Uslu R, Turhal S. Bilici A, et al. Among authors: sezgin goksu s. Cancer Invest. 2022 Feb;40(2):199-209. doi: 10.1080/07357907.2021.2017952. Epub 2021 Dec 22. Cancer Invest. 2022. PMID: 34894960
Cisplatin plus paclitaxel and bevacizumab versus carboplatin plus paclitaxel and bevacizumab for the first-line treatment of metastatic or recurrent cervical cancer.
Ilhan Y, Tatli AM, Teker F, Onder AH, Kose F, Geredeli C, Karaagac M, Kaplan MA, Inanc M, Goktas Aydin S, Kargi A, Arak H, Ozturk B, Besen AA, Selvi O, Korkmaz M, Oruc Z, Bozkurt O, Bilici A, Bayram S, Dae SA, Ozdogan M, Coskun HS, Sezgin Goksu S. Ilhan Y, et al. Among authors: sezgin goksu s. Int J Gynecol Cancer. 2022 Apr 4;32(4):502-507. doi: 10.1136/ijgc-2021-003165. Int J Gynecol Cancer. 2022. PMID: 35086927
Impact of adding pertuzumab to trastuzumab plus chemotherapy in neoadjuvant treatment of HER2 positive breast cancer patients: a multicenter real-life HER2PATH study.
Bilici A, Olmez OF, Kaplan MA, Oksuzoglu B, Sezer A, Karadurmus N, Cubukcu E, Sendur MAN, Aksoy S, Erdem D, Basaran G, Cakar B, Shbair ATM, Arslan C, Sumbul AT, Sezgin Goksu S, Karadag I, Cicin I, Gumus M, Selcukbiricik F, Harputluoglu H, Demirci U. Bilici A, et al. Among authors: sezgin goksu s. Acta Oncol. 2023 Apr;62(4):381-390. doi: 10.1080/0284186X.2023.2202330. Epub 2023 Apr 21. Acta Oncol. 2023. PMID: 37083566
20 results